Lv1
10 积分 2020-12-31 加入
MET Amplification Attenuates Lung Tumor Response to Immunotherapy by Inhibiting STING
1天前
待确认
A first-in-class β-glucuronidase responsive conjugate for selective dual targeted and photodynamic therapy of bladder cancer
29天前
已完结
The Geography of Pharmaceutical Innovation
1个月前
已完结
Synthesis of novel indolizine, diazepinoindolizine and Pyrimidoindolizine derivatives as potent and selective anticancer agents
1个月前
已完结
From challenges to solutions: A review of fourth-generation EGFR tyrosine kinase inhibitors to overcome the C797S triple mutation in non-small cell lung cancer
2个月前
已完结
Discovery and preclinical evaluations of TQB3616, a novel CDK4-biased inhibitor
6个月前
已完结
SMARCA2 protein: Structure, function and perspectives of drug design
7个月前
已完结
Discovery of FHD-286, a First-in-Class, Orally Bioavailable, Allosteric Dual Inhibitor of the Brahma Homologue (BRM) and Brahma-Related Gene 1 (BRG1) ATPase Activity for the Treatment of SWItch/Sucrose Non-Fermentable (SWI/SNF) Dependent Cancers
7个月前
已完结
An Expedient Approach for the Synthesis of TAM and MET Receptor Kinase Inhibitor’s Core (R)-2-((4-(4-Amino-2-fluorophenoxy)-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)amino)propan-1-ol
7个月前
已完结
Incidence of grade 3-4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis
8个月前
已完结
皖公网安备34019202002308
